If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
== Function == Generally, S100A12 has a significant anti-infectious and antibacterial role that is related to its ability to uptake ions. For example, it inhibits the spread and virulence of H. pylori.
Muscle cells work by detecting a flow of electrical impulses from the brain which signals them to contract through the release of calcium by the sarcoplasmic reticulum. Fatigue (reduced ability to generate force) may occur due to the nerve, or within the muscle cells themselves.
It is a situation similar to lipocalins (from Greek lipos=fat and Greek kalyx=cup), where the name designates a superfamily of widely distributed and heterogenous proteins, which transport small hydrophobic molecules including steroids and lipids. However, in contrast to lipocalins, the “CSP” family refers to homogenous evolutionary-well conserved proteins with characteristic sequence (4 cysteines), tissue profiling (ubiquitously expressed), and rather highly diverse binding properties (not only to long fatty acids (FAs) and straight lipid chains, but also to cyclic compounds such as cinnamaldehyde) [34]. Therefore, it is rather difficult to name groups and sub-groups within the CSP family, although numerous CSP proteins are mainly produced in the gut and the fat body that are considered as the insect body’s principle storage organs for energy in the forms of FAs and lipids, which are mobilized through lipolysis process to provide fuel to other organs to develop, regenerate or grow and/or to respond to an infectious agent [4, 14, 50]. In moths, specific lipid chains are mobilized for pheromone synthesis [9-14].
Headaches Enlargement of the hands, feet, nose, lips, and ears, and a general thickening of the skin Soft tissue swelling of internal organs, notably the heart with the attendant weakening of its muscularity, and the kidneys, also the vocal cords resulting in a characteristic thick, deep voice and slowing of speech Generalized expansion of the skull at the fontanelle Pronounced brow protrusion, often with ocular distension (frontal bossing) Pronounced lower jaw protrusion (prognathism) with attendant macroglossia (enlargement of the tongue) and teeth spacing Hypertrichosis, hyperpigmentation and hyperhidrosis Skin tags Carpal tunnel syndrome
Sources: en.wikipedia.org
== Evolved adaptations == The human penis has been argued to have several evolutionary adaptations that maximise reproductive success and minimise sperm competition. Sperm competition is where the sperm of two males simultaneously occupy the reproductive tract of a female and they compete to fertilise the egg. If sperm competition results in the rival male's sperm fertilising the egg, cuckoldry could occur. This is the process whereby males unwittingly invest their resources into offspring of another male and, evolutionarily speaking, should be avoided. The most researched human penis adaptations are penis size and semen displacement.
=== November === 2 November – Kemi Badenoch wins the Conservative leadership election, defeating rival Robert Jenrick after securing the support of party members. 3 November – Police Scotland say they have received a fresh allegation concerning a non-recent sexual assault against former First Minister of Scotland Alex Salmond. 5 November – The Office for Budget Responsibility said that HM Treasury should have disclosed a £9.5bn overspend before the budget in March "by law". A Treasury spokesperson said it had acted "within the law". It is announced that Northern Ireland First Minister Michelle O'Neill will become the first senior Sinn Féin figure to take part in an official Remembrance Sunday ceremony in Belfast, which is scheduled to take place on 10 November. 6 November – Following the freebies scandal, Prime Minister Sir Keir Starmer announces a tightening of the rules regarding ministers' acceptance of gifts and hospitality. Starmer congratulates Donald Trump on his election as President of the United States, and says that a strong UK–US relationship is "crucial". John Swinney, the First Minister of Scotland, also offers Trump his congratulations. Kemi Badenoch attends her first Prime Minister's Questions as Leader of the Opposition. Welsh Labour MP Steve Witherden apologises after he was reprimanded for drinking from a carton of milk in the House of Commons. 7 November – Foreign Secretary David Lammy dismisses previous criticism of Donald Trump as "old news". He had described Trump as a "tyrant" and "a woman-hating, neo-Nazi-sympathising sociopath".
All nuclear data not otherwise stated is from the standard source: There are 42 known isotopes of polonium (84Po), all radioactive, stretching from 186Po to 227Po. The isotopes 210 through 218 occur naturally in the four principal decay chains. In terms of curies they are mostly of even mass number, coming from uranium-238 and thorium-232, with smaller amounts of 211 and 215 from uranium-235, and very little with mass number 213 coming from neptunium-237, and much less with mass number 217 coming from a rare branch of the neptunium decay chain. 210Po has the longest half-life by far (138.376 days) and is, therefore, the most abundant by far in terms of moles or mass. It is also the most easily synthesized isotope, by neutron capture on natural bismuth, and so by far the most abundant artificial isotope as well. Two other isotopes have longer lives: 209Po with a half-life of 124 years and 208Po with a half-life of 2.898 years. Both are made by using a cyclotron to bombard bismuth with protons.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.